慢性肾脏病中的盐皮质激素受体拮抗作用
本文综述了盐皮质激素受体(MR)过度激活在慢性肾脏病(CKD)进展中的作用,并探讨了甾体类MR拮抗剂(螺内酯、依普利酮)在CKD各期的安全性与疗效,以及新型非甾体类MR拮抗剂非奈利酮的作用机制和临床证据。
要点
- MR过度激活可导致水钠潴留、高血压及心肾纤维化,促进CKD进展。
- 非奈利酮在动物模型中较甾体类MRA具有更优的风险获益比。
- III期试验显示非奈利酮改善CKD合并2型糖尿病患者的肾衰竭和心血管结局。
核心结论
- MR拮抗是延缓CKD进展和改善心血管预后的有吸引力的治疗策略。
- 非奈利酮作为新型非甾体MRA,在CKD合并2型糖尿病患者中改善肾脏和心血管结局。
研究设计与样本
- 综述性文章,汇总动物模型、II期和III期临床试验证据。
主要发现
- 动物模型中MR过度激活增加钠潴留和高血压,并诱发肾脏、血管和心脏的炎症与纤维化。
- 在CKD动物模型中,非奈利酮较螺内酯和依普利酮具有更有利的风险获益比。
- 在2型糖尿病合并心/肾疾病患者中,II期试验显示非奈利酮的获益超过MR拮抗的风险。
- 在CKD合并2型糖尿病患者中,大型III期试验显示非奈利酮较安慰剂改善肾衰竭和心血管结局。
临床怎么用
- 对于CKD合并2型糖尿病患者,可考虑使用非奈利酮以改善肾脏和心血管结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The overactivation of the mineralocorticoid receptor (MR) in animal models of chronic kidney disease (CKD) increases sodium retention and hypertension and provokes inflammation and fibrosis in the kidneys, blood vessels, and the heart; these processes play an important role in the progression of cardiorenal disease. Accordingly, blockade of the MR is an attractive therapeutic intervention to retard the progression of CKD and improve cardiovascular morbidity and mortality. Finerenone is a novel, nonsteroidal MR antagonist (MRA) with a unique mode of action that is distinct from currently available steroidal MRAs. In animal models of CKD, finerenone has a more favorable benefit/risk ratio as compared with the steroidal MRAs such as spironolactone and eplerenone. In patients with type 2 diabetes and heart and/or kidney disease, phase II trials have revealed that compared with spironolactone, eplerenone, or placebo, finerenone displays benefits that exceed the risks of MR antagonism. In patients with CKD and type 2 diabetes, a large phase III trial has shown that, compared with placebo, finerenone improved kidney failure and cardiovascular outcomes. In the first part of this article, we explore the safety and efficacy of spironolactone and eplerenone in early- and late-stage CKD. In the second part, we describe the mechanism of action of finerenone and discuss the promising role of this nonsteroidal MRA as a novel therapeutic opportunity to improve clinical outcomes in patients with CKD.
引用
- Georgianos PI, Agarwal R. Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease. Kidney Int Rep. 2021. PMID: 34514191. doi:10.1016/j.ekir.2021.05.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。